Sanjiv.Parant.

{
  "main_header": {
    "sid": 328426,
    "name": "Sanjiv.Parant.",
    "stock_name": "Sanjiv.Parant.",
    "full_name": "Sanjivani Paranteral Ltd",
    "name_url": "stocks-analysis/sanjivparant",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "132.25",
    "chg": -17.65,
    "chgp": "-11.77%",
    "dir": -1,
    "prev_price": "149.90",
    "mcapval": "161.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531569,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE860D01013",
    "curr_date": "May 15",
    "curr_time": "",
    "bse_nse_vol": "65.75 k",
    "exc_status": "Active",
    "traded_date": "May 15, 2026",
    "traded_date_str": "2026 05 15",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sanjivparant-328426-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Sanjivani Paranteral Q4 FY26: Sharp Profit Decline Raises Concerns Despite Revenue Growth",
        "link": "https://www.marketsmojo.com/news/result-analysis/sanjivani-paranteral-q4-fy26-sharp-profit-decline-raises-concerns-despite-revenue-growth-3992760",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SanjivaniParant_quaterlyResult_3992760.png",
        "date": "2026-05-15 09:47:37",
        "description": "Sanjivani Paranteral Ltd., a WHO-GMP certified pharmaceutical manufacturer specialising in injectables and oral solids, reported deeply disappointing results for Q4 FY26, with net profit plummeting 74.89% year-on-year to ₹0.55 crores from ₹2.19 crores in the corresponding quarter last year. The sequential decline was even more alarming, with profits collapsing 80.22% from ₹2.78 crores in Q3 FY26. The micro-cap company, valued at ₹161.00 crores, saw its shares tumble 12.64% following the results announcement, reflecting investor concern over the sharp deterioration in profitability despite a respectable 29.60% revenue growth for the full year FY25."
      },
      {
        "title": "Sanjivani Paranteral Ltd Falls to 52-Week Low of Rs 128.2 as Sell-Off Deepens",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sanjivani-paranteral-ltd-stock-falls-to-52-week-low-of-rs1282-3992267",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SanjivaniParant_priceRelatedfactors_3992267.png",
        "date": "2026-05-15 09:38:41",
        "description": "For the second consecutive session, Sanjivani Paranteral Ltd has seen its share price decline sharply, hitting a fresh 52-week low of Rs 128.2 on 15 Jun 2026. This drop comes amid a broader market rally, underscoring the stock's distinct weakness within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Sanjivani Paranteral Ltd Upgraded to Hold on Improved Valuation and Financial Metrics",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sanjivani-paranteral-ltd-upgraded-to-hold-on-improved-valuation-and-financial-metrics-3988565",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SanjivaniParant_mojoScore_3988565.png",
        "date": "2026-05-13 08:01:42",
        "description": "Sanjivani Paranteral Ltd has seen its investment rating upgraded from Sell to Hold, driven primarily by an improved valuation profile, robust financial trends, and solid quality metrics. Despite recent share price weakness, the company’s fundamentals and operational efficiency have strengthened, prompting a reassessment of its market stance."
      },
      {
        "title": "Sanjivani Paranteral Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sanjivani-paranteral-ltd-valuation-shifts-signal-renewed-price-attractiveness-3988403",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SanjivaniParant_valuationdot_3988403.png",
        "date": "2026-05-13 08:00:24",
        "description": "Sanjivani Paranteral Ltd has witnessed a notable shift in its valuation parameters, moving from a previously fair valuation to an attractive one, as reflected in its updated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change, coupled with a recent upgrade in its Mojo Grade from Sell to Hold, suggests a recalibration of market sentiment towards the pharmaceuticals and biotechnology micro-cap, despite recent price volatility and underperformance relative to the Sensex."
      },
      {
        "title": "When is the next results date for Sanjivani Paranteral Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-sanjivani-paranteral-ltd-3978464",
        "imagepath": "",
        "date": "2026-05-06 23:16:06",
        "description": "The next results date for Sanjivani Paranteral Ltd is scheduled for 14 May 2026...."
      },
      {
        "title": "Sanjivani Paranteral Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sanjivani-paranteral-ltd-is-rated-sell-3972531",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SanjivaniParant_mojoScore_3972531.png",
        "date": "2026-05-02 10:10:38",
        "description": "Sanjivani Paranteral Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Apr 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 02 May 2026, providing investors with the latest perspective on the company’s position in the market."
      },
      {
        "title": "Sanjivani Paranteral Ltd Downgraded to Sell Amid Bearish Technicals and Market Underperformance",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sanjivani-paranteral-ltd-downgraded-to-sell-amid-bearish-technicals-and-market-underperformance-3955037",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SanjivaniParant_mojoScore_3955037.png",
        "date": "2026-04-21 08:03:08",
        "description": "Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 20 Apr 2026. This decision follows a comprehensive reassessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals. Despite some positive long-term growth indicators, the stock’s recent performance and technical signals have raised concerns among analysts, prompting a cautious stance."
      },
      {
        "title": "Sanjivani Paranteral Ltd Gains 6.20%: Technical Upgrade and Valuation Shift Drive Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sanjivani-paranteral-ltd-gains-620-technical-upgrade-and-valuation-shift-drive-momentum-3952794",
        "imagepath": "",
        "date": "2026-04-19 09:00:41",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>13 Apr:</strong> Stock opens at Rs.167.00, declines 1.45%</p>\n                    <p><strong>15 Apr:</strong> Sharp rally to Rs.181.40 (+8.62%) following rating upgrade</p>\n                    <p><strong>16 Apr:</strong> Valuation shifts to expensive amid strong price rally</p>\n                    <p><strong>17 Apr:</strong> Week closes at Rs.179.95, marginal decline of 0.14%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.167.00</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.179...."
      },
      {
        "title": "Sanjivani Paranteral Ltd Upgraded to Hold by MarketsMOJO on Technical Improvements",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sanjivani-paranteral-ltd-upgraded-to-hold-by-marketsmojo-on-technical-improvements-3948216",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SanjivaniParant_mojoScore_3948216.png",
        "date": "2026-04-16 08:02:53",
        "description": "Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 15 Apr 2026. This shift reflects nuanced changes across four key parameters: quality, valuation, financial trend, and technicals. Despite a challenging year marked by underperformance relative to the broader market, the company’s improving fundamentals and technical indicators have prompted a reassessment of its outlook."
      }
    ],
    "total": 225,
    "sid": "328426",
    "stock_news_url": "https://www.marketsmojo.com/news/sanjivani-paranteral-328426"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "12-May-2026",
      "details": "Refer attached document",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results Along With Audit Report For The Fourth Quarter And Financial Year Ended 31St March 2026",
      "datetime": "05-May-2026",
      "details": "Sanjivani Paranteral Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 inter alia to consider and approve 1. To approve Audited Standalone and Consolidated Financial Results along with Audit Report for the Fourth Quarter and Financial Year Ended 31st March 2026 pursuant to Regulation 33 of the Listing Obligation and Disclosure Requirement 2015; 2. Any other matter with the permission of Chair and with the consent of a majority of the Directors present in the Meeting including at least one Independent Director.",
      "source": "BSE"
    },
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "28-Apr-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Sanjivani Paranteral Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24300MH1994PLC081752</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: RAVIKUMAR BOGAM <br/> Designation: COMPANY SECRETARY <br/> EmailId: INFO@SANJIVANI.CO.IN</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: PRITESH JAIN <br/> Designation: CHIEF FINANCIAL OFFICER <br/> EmailId: PRITESH.JAIN@SANJIVANI.CO.IN</div> </div> <div> <br/> Date: 28/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Sanjivani Paranteral Ltd has declared <strong>5%</strong> dividend, ex-date: 19 Sep 25",
          "dt": "2025-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Sanjivani Paranteral Q4 FY26: Sharp Profit Decline Raises Concerns Despite Revenue Growth

2026-05-15 09:47:37

Sanjivani Paranteral Ltd., a WHO-GMP certified pharmaceutical manufacturer specialising in injectables and oral solids, reported deeply disappointing results for Q4 FY26, with net profit plummeting 74.89% year-on-year to ₹0.55 crores from ₹2.19 crores in the corresponding quarter last year. The sequential decline was even more alarming, with profits collapsing 80.22% from ₹2.78 crores in Q3 FY26. The micro-cap company, valued at ₹161.00 crores, saw its shares tumble 12.64% following the results announcement, reflecting investor concern over the sharp deterioration in profitability despite a respectable 29.60% revenue growth for the full year FY25.

Read full news article

Sanjivani Paranteral Ltd Falls to 52-Week Low of Rs 128.2 as Sell-Off Deepens

2026-05-15 09:38:41

For the second consecutive session, Sanjivani Paranteral Ltd has seen its share price decline sharply, hitting a fresh 52-week low of Rs 128.2 on 15 Jun 2026. This drop comes amid a broader market rally, underscoring the stock's distinct weakness within the Pharmaceuticals & Biotechnology sector.

Read full news article

Sanjivani Paranteral Ltd Upgraded to Hold on Improved Valuation and Financial Metrics

2026-05-13 08:01:42

Sanjivani Paranteral Ltd has seen its investment rating upgraded from Sell to Hold, driven primarily by an improved valuation profile, robust financial trends, and solid quality metrics. Despite recent share price weakness, the company’s fundamentals and operational efficiency have strengthened, prompting a reassessment of its market stance.

Read full news article

Sanjivani Paranteral Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-05-13 08:00:24

Sanjivani Paranteral Ltd has witnessed a notable shift in its valuation parameters, moving from a previously fair valuation to an attractive one, as reflected in its updated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change, coupled with a recent upgrade in its Mojo Grade from Sell to Hold, suggests a recalibration of market sentiment towards the pharmaceuticals and biotechnology micro-cap, despite recent price volatility and underperformance relative to the Sensex.

Read full news article

When is the next results date for Sanjivani Paranteral Ltd?

2026-05-06 23:16:06

The next results date for Sanjivani Paranteral Ltd is scheduled for 14 May 2026....

Read full news article

Sanjivani Paranteral Ltd is Rated Sell

2026-05-02 10:10:38

Sanjivani Paranteral Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Apr 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 02 May 2026, providing investors with the latest perspective on the company’s position in the market.

Read full news article

Sanjivani Paranteral Ltd Downgraded to Sell Amid Bearish Technicals and Market Underperformance

2026-04-21 08:03:08

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 20 Apr 2026. This decision follows a comprehensive reassessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals. Despite some positive long-term growth indicators, the stock’s recent performance and technical signals have raised concerns among analysts, prompting a cautious stance.

Read full news article

Sanjivani Paranteral Ltd Gains 6.20%: Technical Upgrade and Valuation Shift Drive Momentum

2026-04-19 09:00:41

Key Events This Week

13 Apr: Stock opens at Rs.167.00, declines 1.45%

15 Apr: Sharp rally to Rs.181.40 (+8.62%) following rating upgrade

16 Apr: Valuation shifts to expensive amid strong price rally

17 Apr: Week closes at Rs.179.95, marginal decline of 0.14%

Week Open

Rs.167.00

Week Close

Rs.179....

Read full news article

Sanjivani Paranteral Ltd Upgraded to Hold by MarketsMOJO on Technical Improvements

2026-04-16 08:02:53

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 15 Apr 2026. This shift reflects nuanced changes across four key parameters: quality, valuation, financial trend, and technicals. Despite a challenging year marked by underperformance relative to the broader market, the company’s improving fundamentals and technical indicators have prompted a reassessment of its outlook.

Read full news article

View All News